Vorasidenib is an orally available small-molecule inhibitor of mutated isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) enzymes, primarily utilized in the treatment of specific gliomas and other hematologic… Read more



Vorasidenib is an orally available small-molecule inhibitor of mutated isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) enzymes, primarily utilized in the treatment of specific gliomas and other hematologic malignancies. This category offers high-quality reference standards essential for the rigorous analytical testing and quality control of this therapeutic agent. Pharmaceutical laboratories rely on these materials, including the parent API, related process and degradation impurities, and stable isotope labelled compounds, to support impurity profiling and method validation. The inclusion of deuterated isotopologues allows for precise quantification in complex bioanalytical assays, ensuring accuracy during drug development and stability testing. By providing comprehensive standards such as vorasidenib-related impurities and synthetic precursors, this collection supports the critical requirements of pharmaceutical research and the maintenance of regulatory compliance in potency and purity evaluations.